Thyroid Cancer

CHICAGO — Radiofrequency ablation remains a safe and viable treatment option for certain patients with thyroid cancer, according to a presenter at the Annual Meeting of the American Thyroid Association.

CHICAGO — Redifferentiation therapy with MEK inhibitor and/or BRAF inhibitor therapy resensitized some patients with metastatic radioactive iodine-refractory thyroid cancer to radioactive iodine, according to retrospective study results presented at the Annual Meeting of the American Thyroid Association.

CHICAGO — Apatinib demonstrated encouraging clinical activity among Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer, according to results of a small phase 2 study presented at the Annual Meeting of the American Thyroid Association.

CHICAGO — In this video exclusive, Endocrine Today Editorial Board Member Stephanie L. Lee, MD, PhD, FACE, ECNU, professor of medicine and director of thyroid health in the section of endocrinology, diabetes and nutrition at Boston Medical Center, discusses four important studies presented at the American Thyroid Association Annual Meeting.

CHICAGO — Research is the backbone of the medical field. Through research, breakthroughs are made to discover how and why diseases develop and how to treat these conditions. For Sissy M. Jhiang, PhD, a professor in the department of physiology and cell biology at The Ohio State University College of Medicine, her work on thyroid cancer research has helped push the field forward, particularly in terms of genetics, thyroid tumor development and radioiodine therapy.

CHICAGO — The American Thyroid Association’s annual Van Meter Award, presented to an investigator younger than 45 years who has made outstanding contributions to thyroid research, was conferred on a cancer epidemiologist for her work elucidating the contributions of environment and lifestyle, particularly obesity, to the rising incidence of thyroid cancer. The 2019 recipient, kept secret until the award lecture at the annual meeting, is Cari Kitahara, PhD, an investigator in the Division of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, of NIH’s National Cancer Institute (NCI).

CHICAGO — Douglas S. Ross, MD, co-director of Thyroid Associates at Massachusetts General Hospital, received the 2019 Paul Starr Award during the Annual Meeting of the American Thyroid Association.

CHICAGO— In this video exclusive, Naifa Lamki Busaidy, MD, FACP, FACE, associate professor in the department of endocrine neoplasia and hormonal disorders at The University of Texas MD Anderson Cancer Center in Houston, discusses recent peer-reviewed research that has had an impact on medical thyroidology — from hypothyroidism to thyroid cancer.

CHICAGO— Adults with thyroid cancer have been treated more frequently with hemithyroidectomy and are receiving fewer completion procedures, particularly after the 2015 update to the guideline from the American Thyroid Association, according to findings presented at the annual meeting of the American Thyroid Association.

CHICAGO — The Wnt/beta-catenin signaling pathway may play an important role in the progression of BRAF V600E-mediated papillary thyroid cancer, according to study results presented at the Annual Meeting of the American Thyroid Association.